Enanta Pharmaceuticals, Inc. (ENTA)

Enanta Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is October - September.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Market Capitalization	115	220	235	1,075	1,148	919
Market Cap Growth	-38.50%	-6.67%	-78.12%	-6.39%	24.98%	-22.29%
Enterprise Value	120	173	73	809	784	494
Last Close Price	5.71	10.36	11.17	51.87	56.81	45.78
PS Ratio	1.82	3.25	2.97	12.48	11.83	7.50
PB Ratio	1.09	1.70	1.09	3.35	2.88	2.02
P/TBV Ratio	1.09	1.70	1.09	3.35	2.88	2.02
P/FCF Ratio	-	-	-	-	162.84
P/OCF Ratio	-	-	-	-	129.64
EV/Sales Ratio	1.80	2.56	0.93	9.39	8.08	4.03
EV/FCF Ratio	-	-	-	-	87.53
Debt / Equity Ratio	1.98	1.76	1.03	0.08	0.02	0.02
Debt / FCF Ratio	-	-	-	-	-	1.70
Asset Turnover	0.17	0.16	0.19	0.21	0.21	0.25
Quick Ratio	5.24	4.99	6.52	10.00	8.43	17.52
Current Ratio	5.47	5.21	6.73	10.45	8.82	18.08
Return on Equity (ROE)	-69.10%	-67.16%	-49.74%	-33.78%	-18.48%	-7.88%
Return on Assets (ROA)	-17.75%	-18.13%	-20.47%	-19.01%	-14.81%	-5.33%
Return on Capital (ROIC)	-18.64%	-19.16%	-21.79%	-20.52%	-15.72%	-5.60%
Earnings Yield	-91.00%	-52.86%	-56.90%	-11.33%	-6.88%	-3.94%
FCF Yield	-83.68%	-44.06%	-47.71%	-8.08%	-6.16%	0.61%
Buyback Yield / Dilution	-0.75%	-0.90%	-1.78%	-2.14%	-1.16%	4.90%

Updated Feb 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q